KLF5 and breast carcinoma: As revealed by transwell migration assay, the metastatic ability of MDA‐MB‐231 and MCF‐7 breast cancer cells was greatly decreased after being treated with KLF5 inhibitor ML264 (Figure S3c,d, Supporting Information).